Clinical benefit and cost-efficacy of risk-stratified survivorship navigation to overcome structural barriers to long-term follow-up care
Clinical benefit and cost-efficacy of risk-stratified survivorship navigation to overcome structural barriers to long-term follow-up care
批准号:
10408928
负责人:
HELEN E HESLOP
金额:
$14.98万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
未结题
起止时间:
2007-07-01 至 2025-06-30
关键词:
AddressAdoptedAffectAge-YearsAlgorithmsAreaAwarenessCancer CenterCaringChronicClinicClinicalConflict (Psychology)Cost AnalysisCosts and BenefitsCounselingDataDevelopmentDiagnosisDiagnostic testsEarly DiagnosisEducationEducational BackgroundElectronic Health RecordElementsEnvironmentFailureFutureHealthHospitalsHourHuman ResourcesIncomeIndividualInstitutional PolicyInsuranceInterventionInvestigationLaboratoriesLanguageLate EffectsLearningLifeLife StyleLocationLong-Term SurvivorsLongterm Follow-upMaintenanceMeasuresMedicalMethodsMorbidity - disease rateNeighborhoodsOutcomePatientsPerceptionPoliciesPopulationPopulations at RiskPredictive FactorPreventionPrivatizationProceduresPublishingReportingResourcesRiskRisk ReductionScheduleSchoolsSecondary PreventionSocioeconomic FactorsStructureSurveysSurvivorsSystemTestingTimeTravelVisitWorkbarrier to carebasecancer diagnosiscancer therapycare deliverychildhood cancer survivorcostdeprivationdesigndisadvantaged backgroundethnic minority populationevidence baseexperiencefollow-uphealth care service utilizationhigh riskimprovedintervention costmetropolitannovelnovel strategiespandemic diseasepersonalized strategiespost interventionpreferenceprospectiveracial minorityrelative costrisk stratificationscreeningsociodemographic factorssociodemographicssocioeconomic disadvantagesocioeconomicsstemsurvivorshiptelehealthtooltreatment riskuptakevoucher
中文摘要
尽管迫切需要长期随访护理,但只有三分之一的儿童癌症幸存者(CCS)报告
英文摘要
Despite a critical need for long-term follow-up care, only one-third of childhood cancer survivors (CCS) report
receiving survivor-focused care, and even fewer receive risk-reduction counseling and appropriate screening.
Numerous studies have described barriers experienced by CCS at the individual level, which largely stem from
socioeconomic factors. As a result, at-risk populations have limited opportunities to engage in long-term follow-
up care, placing them at higher risk for treatment-related morbidities. Few studies have successfully tested
effective, sustainable interventions to overcome structural barriers within the cancer center environment,
factors that contribute to CCS outcome disparities by limiting access to survivorship care.
Equitable access to quality survivorship care cannot be achieved without addressing existing barriers to health
care utilization. The objective of our proposal is to evaluate hospital policies and procedures that
disproportionately impact CCS from disadvantaged backgrounds, and identify novel strategies that eliminate,
circumvent, or overcome systematic barriers to CCS entry into long-term follow-up care. Aim 1 will leverage
electronic health record data extraction tools to abstract relevant sociodemographic data from living CCS that
have completed treatment. We will then develop an algorithm for identifying CCS at-risk for suboptimal health
care utilization (defined as failure to enter long-term follow-up care by four years after completing treatment).
To do this, we will use factors predictive of survivorship nonadherence from our previously published work, and
incorporate area-based measures of socioeconomic deprivation. For Aim 2 we will prospectively identify CCS
who are at-risk for suboptimal health care utilization and eligible for entry to long-term follow-up (at least 3
years from end of therapy) who have not yet scheduled a visit in the Long Term Survivor (LTS) Clinic. A
Survivorship Navigator will contact at-risk CCS to complete a survey that assesses structural barriers, data that
will be used to inform development of an LTS Resource Tool Kit. For Aim 3, the Survivorship Navigator will
use the LTS Resource Tool Kit to offer at-risk CCS personalized solutions to the barriers they endorsed in Aim
2. Clinical benefit to the intervention will be assessed by comparing the rates of first LTS visit per eligible at-risk
CCS to rates from historical at-risk CCS controls. The impact of the intervention on cost efficacy will be
determined from the personnel time spent in navigation activities plus Tool Kit-related expenses to the resulting
increase in revenue generated from LTS visits.
We anticipate this project will improve the proportion of eligible at-risk CCS that initiate long-term follow-up
care in the LTS Clinic. Evidence generated by the results of this study will provide practical, sustainable, and,
most importantly, generalizable solutions that maximize survivorship care uptake in at-risk CCS. Future areas
of investigation include assessment of the impact of this intervention on maintenance of long-term follow-up
care beyond the initial visit.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anti-viral and antileukemic T-cell therapy as prophylaxis after HSCT
-
批准号:9069027
-
项目类别:
-
资助金额:$16.02万
-
财政年份:2011
-
负责人:HELEN E HESLOP
-
依托单位:
Anti-viral and antileukemic T-cell therapy as prophylaxis after HSCT
-
批准号:8479213
-
项目类别:
-
资助金额:$16.02万
-
财政年份:2011
-
负责人:HELEN E HESLOP
-
依托单位:
MOST CLOSELY HLA MATCHED ALLOGENEIC VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES (CTL)
-
批准号:8356704
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2010
-
负责人:HELEN E HESLOP
-
依托单位:
CLINICAL TRIAL: ADMINISTRATION OF EBV SPECIFIC CYTOTOXIC T LYMPHOCYTES TO RECIPI
-
批准号:8356760
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2010
-
负责人:HELEN E HESLOP
-
依托单位:
Enhancing T Cell Therapy of Cancer
-
批准号:7845205
-
项目类别:
-
资助金额:$5.94万
-
财政年份:2009
-
负责人:HELEN E HESLOP
-
依托单位:
CLINICAL TRIAL: ADMINISTRATION OF EBV SPECIFIC CYTOTOXIC T LYMPHOCYTES TO RECIPI
-
批准号:8166752
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2009
-
负责人:HELEN E HESLOP
-
依托单位:
CLINICAL TRIAL: AUTOLOGOUS EBV SPECIFIC CTLS FOR THERAPY OF SEVERE CHRONIC EBV I
-
批准号:8166754
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2009
-
负责人:HELEN E HESLOP
-
依托单位:
MOST CLOSELY HLA MATCHED ALLOGENEIC VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES (CTL)
-
批准号:8166725
-
项目类别:
-
资助金额:$0.42万
-
财政年份:2009
-
负责人:HELEN E HESLOP
-
依托单位:
CLINICAL TRIAL: EBV-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR EBV-POSITIVE NASOPHARYN
-
批准号:8166756
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2009
-
负责人:HELEN E HESLOP
-
依托单位:
PROCUREMENT OF TISSUE FOR MAKING EPSTEIN-BARR VIRUS (EBV) SPECIFIC CYTOTOXIC T
-
批准号:8166709
-
项目类别:
-
资助金额:$0.11万
-
财政年份:2009
-
负责人:HELEN E HESLOP
-
依托单位:
CLINICAL TRIAL: AUTOLOGOUS EBV SPECIFIC CTLS FOR THERAPY OF SEVERE CHRONIC EBV I
-
批准号:7950676
-
项目类别:
-
资助金额:$0.27万
-
财政年份:2008
-
负责人:HELEN E HESLOP
-
依托单位:
CLINICAL TRIAL: AUTOLOGOUS EBV SPECIFIC CTLS FOR PROPHYLAXIS AND THERAPY OF EBV
-
批准号:7950584
-
项目类别:
-
资助金额:$0.03万
-
财政年份:2008
-
负责人:HELEN E HESLOP
-
依托单位:
MOST CLOSELY HLA MATCHED ALLOGENEIC VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES
-
批准号:7950672
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2008
-
负责人:HELEN E HESLOP
-
依托单位:
CLINICAL TRIAL: ADMINISTRATION OF EBV SPECIFIC CYTOTOXIC T LYMPHOCYTES TO RECIPI
-
批准号:7950674
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2008
-
负责人:HELEN E HESLOP
-
依托单位:
CLINICAL TRIAL: EBV-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR EBV-POSITIVE NASOPHARYN
-
批准号:7950678
-
项目类别:
-
资助金额:$0.39万
-
财政年份:2008
-
负责人:HELEN E HESLOP
-
依托单位:
Baylor College of Medicine Cancer Center-Cancer Center Support Grant
-
批准号:10293866
-
项目类别:
-
资助金额:$24.85万
-
财政年份:2007
-
负责人:HELEN E HESLOP
-
依托单位:
Cancer Center Administrative Core
-
批准号:10439807
-
项目类别:
-
资助金额:$21.29万
-
财政年份:2007
-
负责人:HELEN E HESLOP
-
依托单位:
Administrative Core
-
批准号:10495076
-
项目类别:
-
资助金额:$17.76万
-
财政年份:2007
-
负责人:HELEN E HESLOP
-
依托单位:
Clinical Research Core
-
批准号:7253732
-
项目类别:
-
资助金额:$6.87万
-
财政年份:2007
-
负责人:HELEN E HESLOP
-
依托单位:
Career Enhancement Program
-
批准号:10704675
-
项目类别:
-
资助金额:$8.88万
-
财政年份:2007
-
负责人:HELEN E HESLOP
-
依托单位:
海外基金